These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 26091765)

  • 1. Noninvasive Identification of ATTRwt Cardiac Amyloid: The Re-emergence of Nuclear Cardiology.
    Maurer MS
    Am J Med; 2015 Dec; 128(12):1275-80. PubMed ID: 26091765
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction.
    González-López E; Gallego-Delgado M; Guzzo-Merello G; de Haro-Del Moral FJ; Cobo-Marcos M; Robles C; Bornstein B; Salas C; Lara-Pezzi E; Alonso-Pulpon L; Garcia-Pavia P
    Eur Heart J; 2015 Oct; 36(38):2585-94. PubMed ID: 26224076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical Phenotyping of Transthyretin Cardiac Amyloidosis with Bone-Seeking Radiotracers in Heart Failure with Preserved Ejection Fraction.
    Chen W; Ton VK; Dilsizian V
    Curr Cardiol Rep; 2018 Mar; 20(4):23. PubMed ID: 29520480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Amyloid transthyretin cardiac amyloidosis: diagnosis and management.
    Di Giovanni B; Gustafson D; Delgado DH
    Expert Rev Cardiovasc Ther; 2019 Sep; 17(9):673-681. PubMed ID: 31478389
    [No Abstract]   [Full Text] [Related]  

  • 5. Transthyretin Cardiac Amyloidosis in Older Americans.
    Brunjes DL; Castano A; Clemons A; Rubin J; Maurer MS
    J Card Fail; 2016 Dec; 22(12):996-1003. PubMed ID: 27769906
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Wild-type transthyretin cardiac amyloidosis (ATTRwt-CA), previously known as senile cardiac amyloidosis: clinical presentation, diagnosis, management and emerging therapies.
    Halatchev IG; Zheng J; Ou J
    J Thorac Dis; 2018 Mar; 10(3):2034-2045. PubMed ID: 29707360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improving strategies for the diagnosis of cardiac amyloidosis.
    Kourelis TV; Gertz MA
    Expert Rev Cardiovasc Ther; 2015; 13(8):945-61. PubMed ID: 26174181
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Echography and scintigraphy using technetium 99m pyrophosphate in the diagnosis of cardiac amyloidosis].
    Guy JM; Lamaud M; Segura C; Berthaud T; Duranton B; Verneyre H
    Ann Cardiol Angeiol (Paris); 1989 Apr; 38(4):215-8. PubMed ID: 2544133
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of technetium Tc 99m pyrophosphate bone scanning in cardiac amyloidosis.
    Gertz MA; Brown ML; Hauser MF; Kyle RA
    Arch Intern Med; 1987 Jun; 147(6):1039-44. PubMed ID: 3036031
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Primary amyloid heart disease presenting as hypertrophic obstructive cardiomyopathy.
    Weston LT; Raybuck BD; Robinowitz M; Brinker JA; Oetgen WJ
    Cathet Cardiovasc Diagn; 1986; 12(3):176-81. PubMed ID: 3015411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nuclear imaging in cardiac amyloidosis.
    Glaudemans AW; Slart RH; Zeebregts CJ; Veltman NC; Tio RA; Hazenberg BP; Dierckx RA
    Eur J Nucl Med Mol Imaging; 2009 Apr; 36(4):702-14. PubMed ID: 19156411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Technetium-99m pyrophosphate cardiac SPECT in endomyocardial biopsy negative cardiac amyloidosis.
    Krupa M; Nguyen R; Revels J; Johnson LS
    Radiol Case Rep; 2018 Oct; 13(5):925-928. PubMed ID: 30093927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Senile cardiac amyloidosis: an underappreciated cause of heart failure.
    Shah S; Dungu J; Dubrey SW
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23391947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early cardiac involvement in senile systemic amyloidosis: a case report.
    Yamano M; Azuma A; Yazaki M; Ikeda S; Sawada T; Matsubara H
    Amyloid; 2008 Mar; 15(1):54-9. PubMed ID: 18266122
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation].
    Hongo M; Yamada H; Okubo S; Hirayama J; Fujii T; Kusama S; Ikeda S
    J Cardiogr; 1985 Mar; 15(1):163-80. PubMed ID: 2999267
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic approach to cardiac amyloidosis.
    Amin HZ; Mori S; Sasaki N; Hirata K
    Kobe J Med Sci; 2014 Jun; 60(1):E5-E11. PubMed ID: 25011639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cardiac amyloidosis: updates in diagnosis and management.
    Mohty D; Damy T; Cosnay P; Echahidi N; Casset-Senon D; Virot P; Jaccard A
    Arch Cardiovasc Dis; 2013 Oct; 106(10):528-40. PubMed ID: 24070600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Negativity of myocardial scintigraphy with technetium-pyrophosphate in a case of primary cardiac amyloidosis].
    Volpi A; Cavalli A; Maggioni AP; Inglese E; Rovelli GE; Neri R; Salvi A
    G Ital Cardiol; 1985 Sep; 15(9):925-9. PubMed ID: 3002892
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amyloidosis of heart and liver: comparison of Tc-99m pyrophosphate and Tc-99m methylene diphosphonate for detection.
    Lee VW; Caldarone AG; Falk RH; Rubinow A; Cohen AS
    Radiology; 1983 Jul; 148(1):239-42. PubMed ID: 6304810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utility and limitations of 3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy in systemic amyloidosis.
    Hutt DF; Quigley AM; Page J; Hall ML; Burniston M; Gopaul D; Lane T; Whelan CJ; Lachmann HJ; Gillmore JD; Hawkins PN; Wechalekar AD
    Eur Heart J Cardiovasc Imaging; 2014 Nov; 15(11):1289-98. PubMed ID: 24939945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.